Gilead Sciences | GILD - Frais De Vente Et D'Administration





Frais De Vente Et D'Administration Changement Date
AbbVie USD 3.84B 205M 2026-09
Agios Pharmaceuticals USD 51.55M 13.09M 2026-06
ALKERMES USD 190.54M 6.1M 2026-09
Alnylam Pharmaceuticals USD 342M 5.92M 2026-09
Amgen USD 1.68B 40M 2026-09
Biogen USD 752M 42.3M 2026-09
BioMarin Pharmaceutical USD 333.64M 61.91M 2026-09
Bristol-Myers Squibb USD 1.7B 127M 2026-09
Coherus Biosciences USD 15M 6.26M 2025-12
Eli Lilly USD 3.12B 305M 2026-09
Gilead Sciences USD 1.52B 70M 2026-06
GlaxoSmithKline GBP 2.16B 39M 2026-09
Glaxosmithkline GBP 2.38B 264M 2026-09
Incyte USD 364.27M 12.54M 2026-09
J&J USD 6.25B 168M 2026-09
Merck USD 2.86B 25M 2026-09
Moderna USD 282M 66M 2026-09
Neurocrine Biosciences USD 366.3M 16.8M 2026-09
Novartis USD 3.08B 163M 2026-09
Pfizer USD 3.28B 132M 2026-09
PTC Therapeutics USD 80.63M 6.74M 2026-06
Puma Biotechnology USD 16.82M 8.15M 2024-09
Regeneron Pharmaceuticals USD 662.1M 14.4M 2026-06
Sangamo BioSciences USD 9.64M 1.83M 2024-06
Sanofi EUR 2.31B 325M 2026-09
Sarepta Therapeutics USD 118.61M 11.01M 2026-09
United Therapeutics USD 184.1M 22.6M 2026-09
Vertex Pharmaceuticals USD 556.3M 25.9M 2026-09